In oral drug formulations, three-dimensional (3D) printing appeared as a revolutionary technology for the creation of customised, flexible and complex dosage forms to conquer key restrictions of conventional pharmaceutical manufacturing. Based on digital models, enabling precise control over drug distribution, porosity and release characteristics, 3D printing generates dosage forms layer-by-layer, which is an additive manufacturing. Some of the important technologies, like fused deposition modelling (FDM), stereolithography, selective laser sintering (SLA), binder jetting, and direct powder extrusion (DPE), have acquired critical attention for their capacity to fabricate tablets with sustained or multi-phase profiles. Spritam is the first 3D printed oral drug that was approved by the FDA. For future products, it validates the clinical potential of the technologies and generates a regulatory precedent. For pediatric and geriatric populations, researchers focus on personalised dosage forms by 3D technology for controlled and targeted drug delivery. Decentralisation manufacturing and decreased dependency on large-scale batch processes are supported by 3D printing with speed up the adoption by continuing innovation in printing methods, regulatory frameworks, and biocompatible polymers. Eventually, 3D printing is expected to revolutionise oral drug delivery by allowing personalised patient-centric pharmaceutical care and efficient.